Clinical Trial Update: Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial evaluating everolimus and sorafenib in recurrent high-grade gliomas has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Glioma
• Brain Tumor
• Glioblastoma

Drugs mentioned

• Everolimus (everolimus)
• Sorafenib (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Brain Tumor, Glioblastoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-02-01